摘要
目的探讨来氟米特联合糖皮质激素治疗IgA肾病的临床疗效,并对比环磷酰胺联合糖皮质激素治疗该病的临床效果。方法将40例IgA肾病患者随机分为两组,每组20例,分别标记为对照组、观察组,对照组患者给予环磷酰胺联合糖皮质激素治疗,观察组患者给予来氟米特联合糖皮质激素治疗,比较两组患者的治疗效果。结果对照组患者有效率为65.0%,观察组患者有效率为75.0%,两组比较差异无统计学意义(P>0.05);对照组不良反应总发生率为50.0%,观察组不良反应总发生率为15.0%,两组比较差异有统计学意义(P<0.05)。结论来氟米特治疗IgA肾病安全、有效,疗效优于环磷酰胺,值得临床推广应用。
Objective： To investigate the treatment clinical efficacy of leflunomide combined with glucocorticoids for IgA nephropathy and compared cyclophosphamide glucocorticoid therapy clinical effects of the disease.Methods： Thirty patients with IgA nephropathy were randomly divided into two groups of 15 cases labeled as the control group and the observation group.And the control group were treated with cyclophosphamide combined with corticosteroids,whilte the observation group were treated with leflunomide combined sugar corticosteroid therapy,and the therapeutic effect of two groups were compared.Results： In the control group,the effective rate of patients was 65.0%,while in the observation group it was 75.0%,and the difference was no statistically significant（P 0.05）;the control group overall rate of adverse reactions was 50.0%,while the observation group was 15.0%,and the difference was statistically significant（P 0.05）.Conclusion： IgA nephropathy leflunomide is safe and effective,and it is more effective than cyclophosphamide,which is worthy of clinical application.
出处
《泰山医学院学报》
CAS
2013年第6期434-436,共3页
Journal of Taishan Medical College
